{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m roflumilast
to a specific field?
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Approved Allergenic Extract
(1994)
Source:
BLA103738
(1994)
Source URL:
First approved in 1994
Source:
BLA103738
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Nickel (II) oxide is an olive gray powder, insoluble in water and soluble in acids. It is produced industrially and used mainly as an intermediate in the production of nickel alloys and as a hydrogenation catalyst. Long-term inhalation of NiO is damaging to the lungs, causing lesions and in some cases cancer.
Status:
US Previously Marketed
Source:
SYNRIBO by TEVA PHARMS INTL
(2012)
Source URL:
First approved in 2012
Source:
SYNRIBO by TEVA PHARMS INTL
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Omacetaxine mepesuccinate (trade name Synribo) formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). It is a natural ester of the alkaloid cephalotaxine from Cephalotaxus harringtonia, now manufactured by hemi-synthesis. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr Abl oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models of wild-type and T315I mutated Bcr-Abl CML.
Status:
US Previously Marketed
Source:
SYNRIBO by TEVA PHARMS INTL
(2012)
Source URL:
First approved in 2012
Source:
SYNRIBO by TEVA PHARMS INTL
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Omacetaxine mepesuccinate (trade name Synribo) formerly named as homoharringtonine or HHT, is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). It is a natural ester of the alkaloid cephalotaxine from Cephalotaxus harringtonia, now manufactured by hemi-synthesis. It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). The mechanism of action of omacetaxine mepesuccinate has not been fully elucidated but includes inhibition of protein synthesis and is independent of direct Bcr-Abl binding. Omacetaxine mepesuccinate binds to the A-site cleft in the peptidyl-transferase center of the large ribosomal subunit from a strain of archaeabacteria. In vitro, omacetaxine mepesuccinate reduced protein levels of the Bcr Abl oncoprotein and Mcl-1, an anti-apoptotic Bcl-2 family member. Omacetaxine mepesuccinate showed activity in mouse models of wild-type and T315I mutated Bcr-Abl CML.
